Personalising diabetes care symposium labelled a ‘success’ at EASD 2021
A distinguished panel of internationally renowned experts have shed light on integrated Personalised Diabetes Management (iPDM), medicines and diagnostics at this year’s European Association for the Study of Diabetes (EASD).
In a three-session long symposium, the panel of scientific experts shared their latest insights and intriguing new topics of integrated personalised diabetes management, treatment options of diabetic retinopathy and prevention of chronic kidney disease.
The 57th annual meeting of the EASD 2021 took place virtually from Monday, September 27 to Friday, October 1, due to the ongoing impact of the COVID-19 pandemic.
The conference, which is the largest and most prominent meeting on diabetes in Europe, offered healthcare professionals from around the world the opportunity to share ideas about cutting-edge research and studies, treatment, and care in diabetes.
Presentation one explored how iPDM drives improved patient-reported outcomes by discussing the importance of glycaemic control, iPDM in diabetes management and what to expect from treatments.
iPDM is set up to overcome therapeutic inertia, improve outcomes and support all involved in the diabetes care continuum. It supports people with diabetes experiencing true relief and helps them spend more time in range. It also enables health care professionals to deliver effective care and helps healthcare systems to ensure efficient and sustainable care provision.
One of the key factors that may lead to fluctuating blood glucose levels, as well as macrovascular and microvascular complications is therapeutic inertia. It can be caused by lack of adherence to treatment, financial and resource issues, very complex regimens, lack of education, to name just a few.
One of the many benefits of iPDM is that it has been shown to facilitate and strengthen collaboration between health care professionals and patients. It encourages time-efficient interpretation of data and therefore better-informed therapy decisions by the caregiver. Evidence suggests that iPDM can also help to prevent acute and to delay long-term complications.
Despite much progress in the field of iPDM, experts have pledged that further work is needed to automatically integrate diverse therapy-relevant data with people-related outcomes. These are aspects that are most important to people living with diabetes and that only they can assess, such as their views of symptoms, their functional status and their health-related quality of life. Only then will personalised care become a reality in the future and improve outcomes in the long term.
According to Professor Kamlesh Khunti, from the University of Leicester, people with diabetes are still not receiving optimal care and type 2 diabetes is associated with poor long-term outcomes including mortality.
Presentation two, Screen, triage, and treat – a digital paradigm for risk stratification in chronic kidney disease (CKD), explored the need for a new approach to CKD, applications of artificial intelligence and enabling risk-based care.
Navdeep Tangri, from the University of Manitoba, shared remarkable advances that were made using machine learning methods to help in one of the most severe secondary complications related to diabetes. Identifying patients with CKD as early as possible is a key factor in preventing kidney failure.
Mr Tangri said: “Current clinical practice is blind to risk. We need this stratification method to shine the spotlight on the highest risk patient so that physicians can focus their energy.”
A predictive tool developed by Roche and IBM based on real-world data has been found to help with this. Following the screening, a tailored risk stratification method, such as the so-called Klinrisk model that was co-developed by Roche Diagnostics, can be used to triage people with CKD and identify those most likely to progress. Once the individuals at highest risk are identified, these people have to be treated early and appropriately. Combining all these methods have been found to pave the way to risk-based care.
The third session, Innovative therapies and future integrated solutions can enhance the management of diabetic eye disease, discussed the ophthalmic complications of diabetes, limitations of screening programmes and future solutions to optimise treatment.
Praveen Patel, of NIHR Biomedical Research Centre at Moorfields Eye Hospital, discussed the current landscape regarding the management of diabetic eye disease with the focus on diabetic retinopathy (DR) and diabetic macular edema (DME). He gave an overview of screening approaches and innovative diagnostics for DR and DME.
Furthermore, he talked about therapeutic options and future integrated solutions to optimise disease management. New therapeutic strategies are in development to relieve the current treatment burden and address the multifactorial nature of eye diseases. However, there is still a significant opportunity to develop new therapies for people with diabetic macular edema and retinopathy to make sure that they maintain better vision in the long term.
Mr Patel said: “The cornerstone of maintaining good vision in the long term is prevention of diabetic eye disease and making sure people understand the importance of systemic disease control.”